ACAD
40.55
+0.33
+0.82%
AEMD
8.75
-0.1
-1.13%
APRI
1.56
+0.06
+4.00%
ARNA
4.19
-0.01
-0.24%
ATEC
1.36
+0.01
+0.74%
CNAT
5.36
+0.04
+0.75%
CRXM
0.5
0.00
0.00%
CYTX
0.66
-0.021
-3.0548%
DXCM
68.68
+0.43
+0.63%
GNMK
9.04
+0.01
+0.11%
HALO
17.45
+0.2
+1.16%
ILMN
205
+1.88
+0.93%
INNV
0.153
+0.003
+1.6667%
INO
8.83
+0.57
+6.90%
ISCO
0.05
0.00
0.00%
ISIS
67.76
+0.59
+0.88%
LGND
89.67
+0.44
+0.49%
LPTN
0.305
+0.008
+2.6599%
MBVX
2.29
-0.09
-3.78%
MEIP
1.87
-0.04
-2.09%
MNOV
4.05
+0.05
+1.25%
MRTX
26.81
+0.97
+3.75%
MSTX
0.49
-0.01
-2.97%
NBIX
42.55
+0.57
+1.36%
NUVA
48.25
+0.02
+0.04%
ONCS
0.233
0.00
0.00%
ONVO
4.65
-0.03
-0.64%
OREX
5.01
+0.01
+0.20%
OTIC
24.86
-6.19
-19.94%
QDEL
21.84
-0.89
-3.92%
RCPT
161.65
+1.54
+0.96%
RGLS
12.85
+0.1
+0.78%
RMD
57.08
-0.24
-0.42%
SCIE
0.02
+0.005
+30.2632%
SPHS
0.845
-0.014
-1.630%
SRNE
12.94
-0.27
-2.04%
TROV
10.93
+0.64
+6.22%
VICL
0.926
+0.036
+4.045%
VOLC
17.99
0.00
0.00%
ZGNX
1.4
0.00
0.00%
ACAD
40.55
+0.33
+0.82%
AEMD
8.75
-0.1
-1.13%
APRI
1.56
+0.06
+4.00%
ARNA
4.19
-0.01
-0.24%
ATEC
1.36
+0.01
+0.74%
CNAT
5.36
+0.04
+0.75%
CRXM
0.5
0.00
0.00%
CYTX
0.66
-0.021
-3.0548%
DXCM
68.68
+0.43
+0.63%
GNMK
9.04
+0.01
+0.11%
HALO
17.45
+0.2
+1.16%
ILMN
205
+1.88
+0.93%
INNV
0.153
+0.003
+1.6667%
INO
8.83
+0.57
+6.90%
ISCO
0.05
0.00
0.00%
ISIS
67.76
+0.59
+0.88%
LGND
89.67
+0.44
+0.49%
LPTN
0.305
+0.008
+2.6599%
MBVX
2.29
-0.09
-3.78%
MEIP
1.87
-0.04
-2.09%
MNOV
4.05
+0.05
+1.25%
MRTX
26.81
+0.97
+3.75%
MSTX
0.49
-0.01
-2.97%
NBIX
42.55
+0.57
+1.36%
NUVA
48.25
+0.02
+0.04%
ONCS
0.233
0.00
0.00%
ONVO
4.65
-0.03
-0.64%
OREX
5.01
+0.01
+0.20%
OTIC
24.86
-6.19
-19.94%
QDEL
21.84
-0.89
-3.92%
RCPT
161.65
+1.54
+0.96%
RGLS
12.85
+0.1
+0.78%
RMD
57.08
-0.24
-0.42%
SCIE
0.02
+0.005
+30.2632%
SPHS
0.845
-0.014
-1.630%
SRNE
12.94
-0.27
-2.04%
TROV
10.93
+0.64
+6.22%
VICL
0.926
+0.036
+4.045%
VOLC
17.99
0.00
0.00%
ZGNX
1.4
0.00
0.00%
Home » Bio: Melinda Richter

Bio: Melinda Richter

As Head of Janssen Labs, Melinda fosters Johnson & Johnson’s external R&D engine and supports the innovation community by creating capital-efficient commercialization models that give early stage companies a big company advantage. By providing infrastructure, services, educational programs and networks in global hotspots, Janssen Labs is the best place to start a biotech company.
Prior to joining Janssen Labs, Melinda was Founder and CEO of Prescience International, an award winning firm dedicated to accelerating research to the patient. Melinda founded Prescience after she had a medical emergency that left her questioning the efficiency and efficacy of the healthcare system. With the tenacity and resolve of a patient looking for a better solution, she set-out to create a better model, which now forms the basis for Janssen Labs’ operational infrastructure. Prior to starting Prescience, Melinda held posts across a variety of functional areas with a global corporation, Nortel Networks, in locations such as Research Triangle Park, New York, Toronto, London, Hong Kong and Beijing before arriving in San Francisco. She also started, raised capital and did large corporate deals for several companies in both the life science and technology space. She holds a Bachelor of Commerce from the University of Saskatchewan in Canada and an MBA from INSEAD in France.